Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands

Abstract Objective To assess the cost effectiveness of cetuximab in third-line treatment of patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) in routine clinical practice compared with best supportive care (BSC). Methods Patients (n = 287) with KRAS wt mCRC treated with cetuximab...

Full description

Bibliographic Details
Main Authors: Carin A. Uyl-de Groot, Elisabeth M. van Rooijen, Cornelis J. A. Punt, Chris P. Pescott
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Health Economics Review
Subjects:
Cost effectiveness
Metastatic colorectal cancer
Cetuximab
KRAS
Third-line treatment
Online Access:http://link.springer.com/article/10.1186/s13561-018-0197-3

Internet

http://link.springer.com/article/10.1186/s13561-018-0197-3

Similar Items